Symposium

7th INTERNATIONAL SYMPOSIUM ON TARGETED ANTICANCER THERAPIES

Amsterdam, The Netherlands, March 23-25, 2009

Presentations
The list of session and lectures below provides access to the presentations (as downloadable PDF) as given during TAT 2009, to the extent the presenting authors have consented to online publication of their slides. Please, do not use these slides in whole or in part for other purposes than your personal reference without the consent of the originating author(s).

Plenary Session 1: Opening ceremony
O01 NDDO Honorary Award Lecture 2009: Targeting VEGF-A to treat cancer and other disorders Napoleone Ferrara, Genentech, South San Francisco, CA, USA
O02 Keynote Lecture: Chemokine receptors and inflammation in cancer Frances R. Balkwill, Barts & The London School of Medicine & Dentistry, London, UK
O03 Keynote Lecture: Targeting insulin, insulin-like growth factors and energy metabolism in cancer treatment Michael Pollak, McGill University, Montreal, Canada
Plenary Session 2: Insulin-like growth factors
O04 Monoclonal antibodies (mAbs) targeting the type I insulin-like growth factor receptor (IGF-1R) Helen Chen, National Cancer Institute, Bethesda, MD, USA
O05 Clinical development of figitumumab (CP-751,871) Antonio Gualberto, Pfizer Global Research and Development, New London, CT, USA
O06 Small molecule insulin-like growth factor inhibitors for anti-cancer therapy Andrew Stephens, et al, OSI Pharmaceuticals, Farmingdale NY and Boulder CO, USA
*O07 Insulin receptor expression is an independent predictor of poor disease outcome in epithelial ovarian cancer** Pauline de Graeff, et al, University Medical Center Groningen, Groningen, The Netherlands
O08 Emerging clinical data – a critical appraisal Ian Judson, The Institute of Cancer Research, Sutton, Surrey, UK
Plenary Session 3: Targeting the cancer stem cell\
O09 Targeting survival pathways in cancer stem cells from solid tumors Ruggero De Maria, Rome, Italy
O10 Notch signalling Anthony Tolcher, START, San Antonio, TX, USA
O12 Targeting the Hedgehog pathway and the Wnt patway in cancer Frederic de Sauvage, Genentech, South San Francisco, CA, USA
Plenary Session 4: Targeting cancer cell death mechanisms
O13 Keynote Lecture: The desirable death… of the cancer cell Guido Kroemer, Institut Gustave Roussy, Villejuif, France
O14 Smac-mimetics and IAP Inhibitors Alain C. Mita, University of Texas Health Science Center - School of Medicine, San Antonio, TX, US
O15 Cell death receptors: the TRAIL pathway in oncology Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
O16 Bcl-2 inhibition Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA
Plenary Session 5: : Miscellaneous targets (1)
O17 RNA-based transcriptional control: mechanisms and therapeutic applications Carlo Catapano, et al, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
O18 Progress of modified oligonucleotide therapeutics in biomedical research Jonathan Hall, Swiss Federal Institute of Technology, Zürich, Switzerland
*O19 A novel small molecule exhibits potent growth suppressive activity through the inhibition of constitutive JAK2/STAT3 signaling in human cancer cells** Jiayuh Lin, et al, The Ohio State University, Columbus, OH, USA
*O20 ARRY-614, a potent p38 map kinase inhibitor, is efficacious in preclinical models of hematologic malignancies and significantly reduces ex vivo cytokine production in humans** Shannon Winski, et al, Array Biopharma, Boulder, CO, USA
*O21 Therapeutic targeting of delta-like ligand 4 (DLL4) as a new angiogenesis-based anti-cancer strategy** Alshad Lalani, et al, Regeneron Pharmaceuticals, Tarrytown, NY, USA
* denotes proffered paper
Plenary Session 6: DNA repair mechanisms
O22 Educational lecture: DNA repair as a drug target in cancer Saul H. Rosenberg, et al, Abbott Laboratories, Abbott Park, IL
O23 Targeting double-strand break repair defects in mouse models of BRCA-associated breast cancer Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
O24 Status of Poly (ADP-ribose) Polymerase (PARP) inhibitors in clinical development Shivaani Kummar, et al, National Cancer Institute, Bethesda, MD, USA
O25 The DNA repair enzyme, Tyrosyl-DNA Phosphodiesterase (Tdp1) as a target for anticancer therapy Yves Pommier, et al, National Cancer Institute, Bethesda, MD, USA


Plenary Session 7: Drug development methodology
O26 Molecular imaging of cancer Peter Choyke, National Cancer Institute, Bethesda, MD, USA
O27 Somatic mutations in human cancer: Genome-wide characterization of structural rearrangements Andrew Futreal, Wellcome Trust Sanger Insitute, Hinxton, UK
O28 Mouse models for lung cancer (presentation not available) Anton Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands
O29* High throughput screening for Wnt/beta-catenin signaling inhibitors (presentation not available) Yonghe L, et al, Southern Research Institute, Birmingham, USA
*O30 Should we include patients with brain metastasis in phase I trials?** Thibault de La Motte Rouge, et al, Institut Gustave Roussy, Villejuif, France
*O31 NCI Common Terminology Criteria for adverse events updated to encompass skin toxicities from targeted therapies** Ann Setser, et al. National Cancer Institute, Rockville, MD, USA

* denotes proffered paper


Plenary Session 8: Miscellaneous targets (2)
O32 The FLT3 tyrosine kinase as a therapeutic target in acute myeloblastic leukemia James D. Griffin, Dana Farber Cancer Institute, Boston, MA, USA
O33 Experimental and approved HDAC inhibitors: a review John Wright, National Cancer Institute, Bethesda, MD, USA
*O34 Identification of novel secreted tumor stroma-derived stimulators of prostate cancer growth** Arne Östman, et al, Karolinska Institutes, Stockholm, Sweden
*O35 Gene expression profiling of prostate cancer cells after single and fractionated doses of radiation for molecular targeted therapy** Molykutty Aryankalayil, et al, National Cancer Institute, Bethesda, MD, USA
O36 A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors - preliminary results Cristiana Sessa, et al, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
* denotes proffered paper


Plenary Session 9: Combining targeted agents in clinical trials
O37 Report MDICT Task Force meeting “Phase I studies of combinations of targeted agents” Hilary Calvert, Northern Institute for Cancer Research, Newcastle, UK
O38 The combination of chemotherapy, bevacizumab and EGFR monoclonal antibodies in colorectal cancer: how to explain the negative outcome? Jolien Tol, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
O39 Combinations of immunotherapy and targeted agents in renal cell cancer Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands
O40 Multi-targeted receptor tyrosine kinase inhibitors plus chemotherapy S. Percy Ivy, National Cancer Institute, Bethesda, MD, USA

Plenary Session 10: Targeting the PI3-mTOR-PTEN signalling pathway
O41 Educational lecture: The (molecular) biology of PTEN/PI-3 kinase/AKT signaling Donald L. Durden, Emory University School of Medicine, Atlanta, GA, USA
O42 PI3 kinase inhibitors: Progress and challenges Paul Workman, The Institute of Cancer Research, Sutton, Surrey, UK
O43 mTOR inhibitors Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain